To strengthen the data suggesting a rebalance of M1/M2 macrophages within the tumor, we performed another assay on day 17 after tumor injection on tumor-infiltrating leukocytes, by carrying out flow cytometry assays on digested tumors to assess the proportion of CD86+ M1 and CD206+ M2 macrophage subsets. This evidence concerns the gene CD86 and neoplasm.